Quantcast

Latest hematologic neoplasms Stories

2014-07-28 16:27:12

FLINT, Mich., July 28, 2014 /PRNewswire/ -- Diplomat, the nation's largest independent specialty pharmacy, announced today that it has been selected as a provider of Zydelig(®) tablets. Zydelig was approved by the U.S. Food and Drug Administration on July 23, 2014 for the treatment of three B-cell blood cancers. "We are pleased to partner with Gilead and be included in the limited panel of distribution for Zydelig," said Gary Kadlec, R.Ph, President of Diplomat. "Our expertise in...

2014-07-28 12:28:51

Approval based on Phase 3 RESONATE data with statistically significant improvements in progression-free and overall survival HORSHAM, Pa., July 28, 2014 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for IMBRUVICA(®) (ibrutinib) capsules for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.[1] The FDA also approved IMBRUVICA for CLL patients with del...

2014-07-25 08:26:13

SUNNYVALE, Calif., July 25, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending the granting of full marketing approval for IMBRUVICA(®) (ibrutinib) in the European Union. IMBRUVICA is being jointly developed and commercialized in the United States by Pharmacyclics and Janssen Biotech, Inc. In Europe, once approved,...

2014-07-23 16:28:25

WHITE PLAINS, N.Y., July 23, 2014 /PRNewswire-USNewswire/ -- Today's U.S. Food and Drug Administration (FDA) approval of idelalisib to treat patients with relapsed chronic lymphocytic leukemia (CLL), follicular lymphoma (FL) and small lymphocytic lymphoma (SLL) is a significant advance for patients with these blood cancers. Idelalisib, which goes by the trade name Zydelig®, is a first-in-class inhibitor of PI3K delta, a protein that is highly expressed in many B-cell malignancies...

2014-05-31 08:21:05

- Data include results from two Phase I studies of ABT-199/GDC-0199 in relapsed/refractory chronic lymphocytic leukemia (CLL) and various subtypes of non-Hodgkin's lymphoma (NHL) NORTH CHICAGO, Ill., May 31, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) released interim results from a Phase Ib clinical trial of ABT-199/GDC-0199, an investigational B-cell lymphoma 2 (BCL-2) selective inhibitor, in combination with rituximab (Abstract 7013). Results showed an overall response rate (ORR) of...

2014-05-31 08:20:48

Oral presentation (Abstract 7014) and poster session (Abstract 7009) featured at the 50th annual meeting of the American Society of Clinical Oncology RARITAN, N.J., May 31, 2014 /PRNewswire/ -- Three year follow-up data from the Phase 1b/2 PCYC-1102 trial of single-agent ibrutinib (IMBRUVICA(®)) suggest continued durable responses in patients with treatment-naive (TN) or relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to data...

2014-05-28 23:16:46

TG02 also shown to be equally active in CLL cells from patients prior to and following twelve months of ibrutinib therapy. San Diego (PRWEB) May 28, 2014 Tragara Pharmaceuticals, Inc. today announced the preliminary results of new preclinical research showing the activity of TG02, the company's unique oral cyclin dependent kinase (CDK) inhibitor, in chronic lymphocytic leukemia (CLL). Researchers at The Ohio State University demonstrated that TG02 is highly active in CLL cells derived...

2014-05-27 16:25:20

-Files patents on markers- TEL AVIV, Israel, May 27, 2014 /PRNewswire/ -- BioLight Life Sciences Investments Ltd. (OTC: BLGTY, TASE: BOLT), a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announced today that Micromedic Technologies (TASE: MCTC), BioLight's cancer diagnostic cluster company, has identified several new genetic markers with high potential to predict necrosis of the jawbone in multiple...

2014-03-27 08:35:29

DUBLIN, Mar. 27, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/48gc9x/therapeutic_class ) has announced the addition of the "Therapeutic Class Overview: Treating Refractory Hematological Malignancies" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Targeting unmet needs in the treatment of cancer/ hematological malignancies through innovative drug development strategies have witnessed favorable...

2014-03-26 08:22:56

DUBLIN, Mar. 26, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/lnx8jm/treating ) has announced the addition of the "Concise Analysis on Treating Refractory Hematological Malignancies for Multiple Myeloma" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) "Concise Analysis on Treating Refractory Hematological Malignancies for Multiple Myeloma", provides an overview of the therapies for Multiple Myeloma (Newly...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related